$PGEN

Tennant Phil sold $132K of PGEN

Tennant Phil (Chief Commercial Officer) sold 30,272 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Tennant Phil
Published Jun 1, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Bearish
medium confidence
Mentioned
$PGEN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENBearishLow
01

Why it matters

The disclosure may slightly influence short-term sentiment among traders monitoring insider behavior, but it does not provide new company fundamentals (no guidance, trial, deal, or regulatory update).

02

Market read

Traders may treat this as a mild negative sentiment datapoint; conviction should be low without corroborating fundamental news.

03

What to watch

No 10b5-1 plan is noted, but the filing still lacks context (e.g., tax events, planned compensation exercises, or prior commitments) that would clarify informativeness.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-01; reflects sale executed 2026-05-28.

Background

SEC Form 4 reports insider transactions; this filing discloses a Chief Commercial Officer’s direct open-market sale of Precigen shares.

Company-level read

Ticker impact

$PGENBearishMedium confidence
Context

Pre-arranged 10b5-1 plan was not used; CCO Phil Tennant sold 30,272 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Likely limited near-term impact; any effect should fade unless followed by additional insider selling or new fundamentals.

Evidence & confidence

This is an SEC Form 4 transaction disclosure with no accompanying company-specific operational or financial update; insider sales often have non-informational explanations.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale was an open-market transaction and may be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • PRECIGEN, INC.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Tennant Phil

    Chief Commercial Officer who sold 30,272 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.